Metabotropic glutamate2/3 (mGlu2/3) receptors, schizophrenia and cognition

European Journal of Pharmacology

Volumn 639, Issue 1-3, 2010, Pages 81-90

  Marek, Gerard J ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Corticostriatal; Hippocampus; Impulsivity; Prefrontal cortex; Thalamocortical

Indexed keywords

1 AMINO 1,3 CYCLOPENTANEDICARBOXYLIC ACID; 2 (2,3 DICARBOXYCYCLOPROPYL)GLYCINE; 2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; 4 [2 AMINO 4 (METHYLTHIO)BUTYRYLAMINO] 2 THIABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID 2,2 DIOXIDE; 4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; 4 AMINO 2 THIABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID 2,2 DIOXIDE; ARIPIPRAZOLE; DIZOCILPINE; EGLUMETAD; KETAMINE; LORAZEPAM; LY 459477; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR AGONIST; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; RISPERIDONE; TALAGLUMETAD; UNCLASSIFIED DRUG; AMINO ACID RECEPTOR STIMULATING AGENT; METABOTROPIC RECEPTOR;

ABSENCE OF SIDE EFFECTS; AUTORADIOGRAPHY; BRAIN CORTEX; BRAIN STEM; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DIFFUSION TENSOR IMAGING; DRUG ACTIVATION; DRUG BIOAVAILABILITY; DRUG RECEPTOR BINDING; ELECTROPHYSIOLOGY; EVOKED RESPONSE; HIPPOCAMPUS; HUMAN; INTRACELLULAR SPACE; LONG TERM DEPRESSION; LONG TERM POTENTIATION; NEOCORTEX; NEUROTRANSMISSION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SOMNOLENCE; THALAMUS; TRANQUILIZING ACTIVITY; ANIMAL; DRUG EFFECT; DRUG POTENTIATION; METABOLISM; PHYSIOLOGY;

ANIMALS; COGNITION; EXCITATORY AMINO ACID AGONISTS; HIPPOCAMPUS; HUMANS; PREFRONTAL CORTEX; RECEPTORS, METABOTROPIC GLUTAMATE; SCHIZOPHRENIA;

EID: 77953613109     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.02.058     Document Type: Review

References (115)

1. Aghajanian G.K. Modeling "psychosis" in vitro by inducing disordered neuronal network activity in cortical brain slices. Psychopharmacology 2009, 206:575-585.
2. Aghajanian G.K., Marek G.J. Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. Neuropharmacology 1997, 36:589-599.
3. Aghajanian G.K., Marek G.J. Serotonin-glutamate interactions: a new target for antipsychotic drugs. Neuropsychopharmacology 1999, 21:S122-S133.
4. 2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release. Brain Res. 1999, 825:161-171.
5. Alexander G.M., Godwin D.W. Presynaptic inhibition of corticothalamic feedback by metabotropic glutamate receptors. J. Neurophysiol. 2005, 94:163-175.
6. Ardayfio P.A., Benvenga M.J., Chaney S.F., Love P.L., Catlow J., Swanson S.P., Marek G.J. The 5-hydroxytryptamine2A receptor antagonist R-(+)-a-(2, 3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl-4-piperidinemethanol (M100907) attenuates impulsivity after both drug-induced disruption (dizocilpine) and enhancement (antidepressant drugs) of differential-reinforcement-of-low-rate 72-s behavior in the rat. J. Pharmacol. Exp. Ther. 2008, 327:891-897.
7. Aultman J.M., Moghaddam B. Distinct contributions of glutamate and dopamine receptors to temporal aspects of rodent working memory using a clinically relevant task. Psychopharmacology 2001, 153:353-364.
8. Battaglia G., Monn J.A., Schoepp D.D. In vivo inhibition of veratridine-induced release of excitatory amino acids by the group II metabotropic agonist LY354740 in rats. Neurosci. Lett. 1997, 229:161-164.
9. Behnisch T., Wilsch V.W., Balschun D., Reymann K.G. The role of group II metabotropic glutamate receptors in hippocampal CA1 long-term potentiation in vitro. Eur. J. Pharmacol. 1998, 356:159-165.
10. 2A receptor-mediated facilitation of synaptic activity in prefrontal cortex. Proc. Natl. Acad. Sci. USA 2007, 104:9870-9875.
11. Benes F.M. Amygdalocortical circuitry in schizophrenia: from circuits to molecules. Neuropsychopharmacol. Rev. 2010, 35:239-257.
12. Benneyworth M.A., Xiang Z., Smith R.L., Garcia E.E., Conn P.J., Sanders-Bush E. A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis. Mol. Pharmacol. 2007, 72:477-484.
13. Berendse H.W., Groenewegen H.J. Restricted cortical termination fields of the midline and intralaminar thalamic nuclei in the rat. Neuroscience 1991, 42:73-102.
14. 2 receptors and serotonergic axons in rat neocortex. Brain Res. 1988, 453:315-328.
15. Bortolotto Z.A., Fitzjohn S., Collingridge G.L. Roles of metabotropic glutamate receptors in LTP and LTD in the hippocampus. Curr. Opin. Neurobiol. 1999, 9:299-304.
16. Boyle J., Trick L., Soo-ampon S., Lilley S., Levine L., Hindmarch I. Evaluation of the cognitive and psychomotor profile of a novel anxiolytic, LY544344, compared to lorazepam in normal volunteers. Eur. Neuropsychopharmacol. 2004, 13:S365. (Supplement).
17. Cagogna M. Distinct properties of presynaptic group II and III metabotropic glutamate receptor-mediated inhibition of perforant pathway-CA1 EPSCs. Eur. J. Neurosci. 2004, 19:2847-2858.
18. Capogna M. Distinct properties of presynaptic group II and III metabotropic glutamate receptor-mediated inhibition of perforant pathway-CA1 EPSCs. Eur. J. Neurosci. 2004, 19:2847-2858.
19. 2A receptors antagonist M100907 prevents impairment in attentional performance by NMDA receptor blockade in the rat prefrontal cortex. Neuropsychopharmacology 2004, 29:1637-1647.
20. Carli M., Baviera M., Invernizzi R.W., Balducci C. Dissociable contribution of 5-HT1A and 5-HT2A receptors in the medial prefrontal cortex to different aspects of executive control such as impulsivity and compulsive perseveration in rats. Neuropsychopharmacology 2006, 31:757-767.
21. Conn P.J., Pin J.-P. Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol. 1997, 37:205-237.
22. Corti C., Crepaldi L., Mion S., Roth A.L., Xuereb J.H., Ferraguti F. Altered dimerization of metabotropic glutamate receptor 3 in schizophrenia. Biological psychiatry 2007, 62:747-755.
23. Crook J.M., Akil M., Law B.C.W., Hyde T.M., Kleinman J.E. Comparative analysis of group II metabotropic glutamate receptor immunoreactivity in Brodmann's area 46 of the dorsolateral prefrontal cortex from patients with schizophrenia and normal subjects. Mol. Psychiatry 2002, 7:157-164.
24. Davies C.H., Clarke V.R.J., Jane D.E., Collingridge G.L. Pharmacology of postsynaptic metabotropic glutamate receptors in rat hippocampal CA1 pyramidal neurones. Br. J. Pharmacol. 1995, 116:1859-1869.
25. Dominguez C., Prieto L., Valli M.J., Massey S.M., Bures M., Wright R.A., Johnson B.G., Andis S.L., Kingston A., Schoepp D.D., Monn J.A. Methyl substitution of 2-aminobicyclo[3.1.0]hexane-2, 6-dicarboxylate (LY354740) determines functional activity at metabotropic glutamate receptors: Identification of a subtype selective mGlu2 receptor agonist. J. Med. Chem. 2005, 48:3605-3612.
26. Dunayevich E., Erickson J., Levine L., Landbloom R., Schoepp D.D., Tollefson G.D. Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology 2008, 33:1603-1610.
27. Ellison-Wright I., Bullmore E. Meta-analysis of diffusion tensor imaging studies in schizophrenia. Schizophr. Res. 2009, 108:3-10.
28. Fell M.J., Svensson K.A., Johnson B.G., Schoepp D.D. Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R, 4S, 5S, 6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4, 6-dicarboxylic acid (LY404039). J. Pharmacol. Exp. Ther. 2008, 326:209-217.
29. Ghose S., Tamminga C.A. Phenomenology and clinical science of schizophrenia. Handbook of Contemporary Neuropharmacology 2007, 251-283. John Wiley & Sons, New York, NY. D.R. Sibley, I. Hanin, M. Kuhar, P. Skolnick (Eds.).
30. Ghose S., Crook J.M., Bartus C.L., Sherman T.G., Herman M.M., Hyde T.M., Kleinman J.E., Akil M. Metabotropic glutamate receptor 2 and 3 gene expression in the human prefrontal cortex and mesencephalon in schizophrenia. Int. J. Neurosci. 2008, 118:1609-1627.
31. Ghose S., Chin R., Gallegos A., Roberts R., Coyle J., Tamminga C. Localization of NAAG-related gene expression deficits to the anterior hippocampus in schizophrenia. Schizophr. Res. 2009, 111:131-137.
32. Ghose S., Gleason K.A., Potts B.W., Lewis-Amezcua K., Tamminga C.A. Differential expression of metabotropic glutamate receptors 2 and 3 in schizophrenia: a mechanism for antipsychotic drug action. Am. J. Psychiatry 2009, 166:812-820.
33. 2A receptor-mediated signalling pathways to affect behavior. Neuron 2007, 53:439-452.
34. Gouzoulis-Mayfrank E., Heekeren K., Neukirch A., Stoll M., Stock C., Obradovic M., Kovar K.-A. Psychological effects of (S)-ketamine and N, N-dimethyltryptamine: A double-blind, cross-over study in healthy volunteers. Pharmacopsychiatry 2005, 38:301-311.
35. Greco B., Invernizzi R.W., Carli M. Phencyclidine-induced impairment in attention and response control depends on the background genotype of mice: reversal by the mGlu(2/3) receptor agonist LY379268. Psychopharmacology 2005, 179:68-76.
36. Grillon C., Cordova J., Levine L.R., Morgan C.A.I. Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans. Psyhcopharmacology 2003, 168:446-454.
37. Grover L.M., Yan C. Evidence for involvement of group II/III metabotropic glutamate receptors in NMDA receptor-independent long-term potentiation in area CA1 of rat hippocampus. J. Neurophysiol. 1999, 82:2956-2969.
38. Gu G., Lorrain D.S., Wei H., Cole R.L., Zhang X., Daggett L.P., Schaffhauser H.J., Bristow L.J., Lechner S.M. Distribution of metabotropic glutamate 2 and 3 receptors in the rat forebrain: Implication in emotional responses and central disinhibition. Brain Res. 2008, 1197:47-62.
39. Gupta D.S., McCullumsmith R.E., Beneyto M., Haroutunian V., Davis K.L., Meador-Woodruff J.H. Metabotropic glutamate receptor protein expression in the prefrontal cortex and striatum in schizophrenia. Synapse 2005, 57:123-131.
40. Harich S., Gross G., Bespalov A. Stimulation of the metabotropic glutamate 2/3 receptor stimulates social novelty discrimination deficits induced by neonatal phencyclidine treatment. Psychopharmacology 2007, 192:511-519.
41. Hermes M.L., Kolaj M., Renaud L. Activation of pre- and postsynaptic group II metabotropic glutamate receptors reduce the excitability of midline thalamic neurons. Society for Neuroscience. 2009 Neuroscience Meeting Planner, Chicago 2009.
42. Higgins G.A., Enderlin M., Haman M., Fletcher P.J. The 5-HT2A receptor antagonist M100, 907 attenuates motor and 'impulsive-type' behaviors produced by NMDA receptor antagonism. Psychopharmacology 2003, 170:309-319.
43. Higgins G.A., Ballard T.M., Kew J.N.C., Richards J.G., Kemp J.A., Adam G., Woltering T., Nakanishi S., Mutel V. Pharmacological manipulation of mGlu2 receptors influences cognitive performance in the rodent. Neuropharmacology 2004, 46:907-917.
44. Homayoun H., Jackson M.E., Moghaddam B. Activation of metabotropic glutamate 2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake rats. J. Neurophysiol. 2005, 93:2005.
45. Huan L., Rowan M.J., Anwyl R. mGluR II agonist inhibition of LTP induction, and mGluR II antagonist inhibition of LTD induction, in the dentate gyrus in vitro. NeuroReport 1997, 8:687-693.
46. Huang C.-C., Hsu K.-S. The role of NMDA receptors in regulating group II metabotropic glutamate receptor-mediated long-term depression in rat medial prefrontal cortex. Neuropharmacology 2008, 54:1071-1078.
47. Huang L., Killbride J., Rowan M.J., Anwyl R. Activation of mGluRII induces LTD via activation of protein kinase A and protein kinase C in the dentate gyrus of the hippocampus in vitro. Neuropharmacology 1999, 38:73-83.
48. Jackson M.E., Homayoun H., Moghaddam B. NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex. Proc. Natl. Acad. Sci. USA 2004, 101:8467-8472.
49. Jakab R.L., Goldman-Rakic P.S. 5-HT2A serotonin receptors in the primate cerebral cortex: Possible site of action of hallucinogens in pyramidal cell apical dendrites. Proc. Natl. Acad. Sci. USA 1998, 95:735-740.
50. Johnson M.P., Barda D., Britton T.C., Emkey R., Hornback W.J., Jagdmann G.E., McKinzie D.L., Nisenbaum E.S., Tizanno J.P., Schoepp D.D. Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s). Psychopharmacology 2005, 179:271-283.
51. Kahn L., Alonso G., Robbe D., Bockaert J., Manzoni O.J. Group 2 metabotropic glutamate receptors induced long term depression in mouse striatal slices. Neurosci. Lett. 2001, 316:178-182.
52. Kamiya H., Shinozaki H., Yamamoto C. Activation of metabotropic glutamate receptor type 2/3 suppresses transmission at rat hippocampal mossy fibre synapses. J. Physiol. 1996, 493:2447-2455.
53. Kew J.N., Pflimlin M.C., Kemp J.A., Mutel V. Differential regulation of synaptic transmission by mGlu2 and mGlu3 at the perforant path inputs to the dentate gyrus and CA1 revealed in mGlu2 -/- mice. Neuropharmacology 2002, 43:215-221.
54. Kilbride J., Huang L.Q., Rowan M.J., Anwyl R. Presynaptic inhibitory action of the group II metabotropic glutamate receptor agonists, LY354740 and DCG-IV. Eur. J. Pharmacol. 1998, 356:149-157.
55. Klodzinska A., Bijak M., Tokarski K., Pilc A. Group II mGlu receptor agonists inhibit behavioral and electrophysiological effects of DOI in mice. Pharmacol. Biochem. Behavior 2002, 73:327-332.
56. Kobayashi K., Manabe T., Takahashi T. Presynaptic long-term depression at the hippocampal mossy fiber-CA3 synapse. Science 1996, 273:648-650.
57. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M., Charney D. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive and neuroendocrine responses. Arch. Gen. Psychiatry 1994, 51:199-214.
58. Krystal J.H., Belger A., D'Souza C., Anand A., Charney D.S., Aghajanian G.K., Moghaddam B. Therapeutic implications of the hyperglutamatergic effects of NMDA antagonists. Neuropsychopharmacology 1999, 21:S143-S157.
59. Krystal J.H., Abi-Saab W., Perry E., D'Souza D.C., Liu N., Guorguieva R., McDougall L., Hunsberger T., Belger A., Levine L., Breier A. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology 2005, 179:303-309.
60. Lea P.M.I., Sarvey J.M. Modulation of epileptiform burst frequency by the metabotropic glutamate receptor subtype mGluR3. Epilepsy Res. 2003, 53:207-215.
61. Lea P.M.I., Wroblewska B., Sarvey J.M., Neale J.H. β-NAAG rescues LTP from blockade by NAAG in rat dentate gyrus via the type 3 metabotropic glutamate receptor. J. Neurophysiol. 2001, 85:1097-1106.
62. Lewis D.A., Volk D.W., Hashimoto T. Selective alterations in prefrontal cortical GABA transmission in schizophrenia: a novel target for the treatment of working memory dysfunction. Psychopharmacology 2004, 2004:143-150.
63. Linden A.M., Shannon H., Baez M., Yu J.L., Koester A., Schoepp D.D. Anxiolytic-like activity of the mGlu2/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out mice. Psychopharmacology 2005, 179:284-291.
64. Lovinger D.M., McCool B.A. Metabotropic glutamate receptor-mediated presynaptic depression at corticostriatal synapses involves mGluR2 or 3. J. Neurophysiol. 1995, 73:1076-1083.
65. Lujan R., Nusser Z., Roberts J.D., Shigemoto R., Somogyi P. Perisynaptic location of metabotropic glutamate receptors mGluR1 and mGluR5 on dendrites and dendritic spines in the rat hippocampus. Eur. J. Neurosci. 1996, 8:1488-1500.
66. Luscher C., Nicoll R.A., Malenka R.C., Muller D. Synaptic plasticity and dynamic modulation of the postsynaptic membrane. Nat. Neurosci. 2000, 3:545-550.
67. Macek T.A., Winder D.G., Gereau R.W., Ladd C.O., Conn P.J. Differential involvement of group II and group III mGluRs as autoreceptors at lateral and medial perforant path synapses. J. Neurophysiol. 1996, 76:3798-3806.
68. Manahan-Vaughan D. Priming of group 2 metabotropic glutamate receptors facilitates induction of long-term depression in the dentate gyrus of freely moving rats. Neuropharmacology 1998, 37:1459-1464.
69. 2A and group II metabotropic glutamate receptors in prefrontal cortex. J. Pharmacol. Exp. Ther. 2000, 292:76-87.
70. Marek G.J., Wright R.A., Gewirtz J.C., Schoepp D.D. A major role for thalamocortical afferents in serotonergic hallucinogen receptor function in the rat neocortex. Neuroscience 2001, 105:379-392.
71. 2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine. Neuropsychopharmacology 2005, 30:2205-2215.
72. Marek G.J., Wright R.A., Johnson B.G., Fell M., Svensson K., Benvenga M., Chaney S., Schoepp D.D., Monn J. Acitvation of mGlu2 receptors mediates the "antipsychotic-like" activity of mGlu2/3 receptor agonists in three psychotomimetic drug models and regional distribution of mGlu2 vs. mGlu3 receptors. Neuropharmacology 2008, 55:608-609.
73. Marek G.J., Wright R.A., Johnson B.G., Fell M.J., Svensson K.A., Benvenga M.J., Chaney S., Schoepp D.D., Monn J. Activation of mGlu2 receptors mediates the "antipsychotic-like" activity of mGlu2/3 receptor agonists in three psychotomimetic drug models and regional distribution of mGlu2 vs. mGlu3 receptors. Neuropharmacology 2008, 55:608-609.
74. Marek G.J., Behl B., Bespalov A.Y., Gross G., Lee Y., Schoemaker H. Glutamatergic (N-methyl-D-aspartate) hypofunctionality in schizophrenia: Too little juice or a miswired brain. Mol. Pharmacol. 2010, 77:317-326.
75. Mateo Z., Porter J.T. Group II metabotropic glutamate receptors inhibit glutamate release at thalamocortical synapses in the developing somatosensory cortex. Neuroscience 2007, 146:1062-1072.
76. Mellentin C., Abraham W.C. Priming stimulation of group II metabotropic glutamate receptors inhibits the subsequent induction of rat hippocampal long-term depression in vitro. Neurosci. Lett. 2007, 2001:13-16.
77. Michelson D., Levine L.R., Dellva M.A., Mesters P., Schoepp D.D., Dunayevich E., Tollefson G.D. Clinical studies with mGlu2/3 receptor agonists: LY354740 compared with placebo in patients with generalized anxiety disorder. Neuropharmacology 2005, 49:257.
78. Miner L.A.H., Backstrom J.R., Sanders-Bush E., Sesack S.R. Ultrastructural localization of serotonin2A receptors in the middle layers of the rat prelimbic prefrontal cortex. Neuroscience 2003, 116:107-117.
79. Moghaddam B., Adams B.W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonists in rats. Science 1998, 281:1349-1352.
80. Mrzljak L., Doherty J. Visualization and pharmacology of allosteric binding sites on metabotropic glutamate receptor 2 (mGluR2) in the rodent and primate brain using functional GTPγS and ligand binding autoradiography. Neuropharmacology 2008, 55:612.
81. Ohishi H., Shigemoto R., Nakanishi S., Mizuno N. Distribution of the messenger RNA for a metabotropic glutamate receptor, mGluR2, in the central nervous system of the rat. Neuroscience 1993, 53:1009-1018.
82. Ohishi H., Shigemoto R., Nakanishi S., Mizuno N. Distribution of the mRNA for a metabotropic glutamate receptor (mGluR3) in the rat brain: an in situ hybridization study. J. Comp. Neurol. 1993, 335:252-266.
83. Ohishi H., Neki A., Mizuno N. Distribution of a metabotropic glutamate receptor, mGluR2, in the central nervous system of the rat and mouse: an immunohistochemical study with a monoclonal antibody. Neurosci. Res. 1998, 30:65-82.
84. Ohnumna T., Augood S.J., Arai H., McKenna P.J., Emson P.C. Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex form normal individuals and patients with schizophrenia. Mol. Brain Res. 1998, 56:207-217.
85. Otani S., Auclair N., Desce J.-M., Roisin M.-P., Crepel F. Dopamine receptors and groups I and II mGluRs cooperate for long-term depression induction in rat prefrontal cortex through converging postsynaptic activation of MAP kinases. J. Neurosci. 1999, 19:9788-9802.
86. Otani S., Daniel H., Takita M., Crepel F. Long-term depression induced by postsynaptic group II metabotropic glutamate receptors linked to phospholipase C and intracellular calcium rises in rat prefrontal cortex. J. Neurosci. 2002, 22:3434-3444.
87. Patil S.T., Zhang L., Martenyi F., Lowe S.L., Jackson K.A., Andreev B.V., Avedisova A.S., Bardenstein L.M., Gurovich I.Y., Morozova M.A., Mosolov S.N., Neznanov N.G., Reznik A.M., Smulevich A.B., Tochilov V.A., Johnson B.G., Monn J.A., Schoepp D.D. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat. Med. 2007, 13:1103-1108.
88. Petralia R.S., Wang Y.-X., Niedzielski A.S., Wenthold R.J. The metabotropic glutamate receptors, mGluR2 and mGluR3, show unique postsynaptic, presynaptic and glial localizations. Neuroscience 1996, 71:949-976.
89. Pin J.-P., Archer F. The metabotropic glutamate receptors: Structure, activation mechanism, and pharmacology. Current Drug Targets CNS Neurol. Disorders 2002, 1:297-317.
90. Poschel B., Manahan-Vaughan D. Group II mGluR-induced long term depression in the dentate gyrus in vivo is NMDA receptor-independent and does not require protein synthesis. Neuropharmacology 2005, 49:1-12.
91. Poschel B., Wroblewska B., Heinemann U., Manahan-Vaughan D. The metabotropic glutamate receptor mGluR3 is critically required for hippocampal long-term depression and modulates long-term potentiation in the dentate gyrus of freely moving rats. Cereb. Cortex 2005, 15:1414-1425.
92. Price C.J., Karayannis T., Pal B.Z., Capogna M. Group II and III mGluRs-mediated presynaptic inhibition of EPSCs recorded from hippocampal interneurons of CA1 stratum lacunosum moleculare. Neuropharmacology 2005, 49:45-56.
93. Rorick-Kehn L.M., Johnson B.G., Burkey J.L., Wright R.A., Calligaro D.O., Marek G.J., Nisenbaum E.S., Catlow J.T., Kingston A.E., Giera D., Herin M.F., Monn J.A., McKinzie D.L., Schoepp D.D. Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: In vitro characterization of agonist (-)-(1R, 4S, 5S, 6S)-4-Amino-2-sulfonylbicyclo[3.1.0]-hexane-4, 6-dicarboxylic acid (LY404039). J. Pharmacol. Exp. Ther. 2007, 321:308-317.
94. Rorick-Kehn L.M., Johnson B.G., Knitowski K.M., Salhoff C.R., Witkin J.M., Perry K.W., Griffey K.I., Tizzano J.P., Monn J.A., McKinzie D.L., Schoepp D.D. In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders. Psychopharmacology 2007, 193:121-136.
95. Santschi L.A., Zhang X.-l., Stanton P.K. Activation of receptors negatively coupled to adenylate cyclase is required for induction of long-term synaptic depression at Schaffer collateral-CA1 synapses. J. Neurobiol. 2006, 66:205-219.
96. Scanziani M., Salin P.A., Vogt K.E., Malenka R.C., Nicoll R.A. Use-dependent increases in glutamate concentration activate presynaptic metabotropic glutamate receptors. Nature 1997, 385:630-634.
97. Schaffhauser H., Rowe B.A., Morales S., Chavez-Noriega L.E., Yin R., Jachec C., Rao S.P., Bain G., Pinkerton A.B., Vernier J.-M., Bristow L.J., Varney M.A., Daggett L.P. Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2. Mol. Pharmacol. 2003, 64:798-810.
98. Schlumberger C., Schafer D., Barberi C., More L., Nagel J., Pietraszek M., Schmidt W.J., Danysz W. Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of posiitive schizophrnenia symptoms and cognition. Behav. Pharmacol. 2009, 20:56-66.
99. Schoepp D.D. Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J. Pharmacol. Exp. Ther. 2001, 299:12-20.
100. Schoepp D.D., Monn J.A., Marek G.J., Aghajanian G.K., Moghaddam B. LY354740: A systemically active mGlu2/3 receptor agonist. CNS Drug Rev. 1999, 5:1-12.
101. Schoepp D.D., Wright R.A., Levine L.R., Gaydos B., Potter W.Z. LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress. Stress 2003, 6:189-197.
102. Shigemoto R., Kinoshita A., Wada E., Nomura S., Ohishi H., Takada M., Flor P.J., Neki A., Abe T., Nakanishi S., Mizuno N. Differential presynaptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus. J. Neurosci. 1997, 17:7503-7522.
103. Spinelli S., Ballard T., Gatti-McArthur S., Richards G.J., Kappa M., Woltering T., Wichmann J., Stadler H., Feldon J., Pryce C.R. Effects of the mGluR2/3 agonist LY354740 on computerized tasks of attention and working memory in marmoset monkeys. Psychopharmacology 2005, 179:292-302.
104. Spooren W.P., Gasparini F., van der Putten H., Koller M., Nakanishi S., Kuhn R. Lack of effect of LY314582 (a group 2 metabotropic glutamate receptor agonist) on phencyclidine-induced locomotor activity in metabotropic glutamate receptor 2 knockout mice. Eur. J. Pharmacol. 2000, 397:R1-R2.
105. Tamaru Y., Nomura S., Mizuno N., Shigemoto R. Distribution of metabotropic glutamate receptor mGluR3 in the mouse CNS: Differential location relative to pre- and postsynaptic sites. Neuroscience 2001, 106:481-503.
106. Testa C.M., Standaert D.G., Young A.B., Penney J.B. Metabotropic glutamate receptor mRNA expression in the basal ganglia of the rat. J. Neurosci. 1994, 14:3005-3018.
107. Turner J.P., Salt T.E. Group III metabotropic glutamate receptors control corticothalamic synaptic transmission in the rat thalamus in vitro. J. Physiol. 1999, 519:2481-2491.
108. Turner J.P., Salt T.E. Group II and III metabotropic glutamate receptors and the control of the nucleus reticularis thalami input to rat thalamocortical neurones in vitro. Neuroscience 2003, 122:459-469.
109. Winstanley C.A., Chudasama Y., Dalley J.W., Theobald D.E.H., Glennon J.C., Robbins T.W. Intra-prefrontal 8-OH-DPAT and M100907 improve visuospatial attention and decrease impulsivity on the five-choice serial reaction time task in rats. Psychopharmacology 2003, 167:304-314.
110. Winstanley C.A., Theobald D.E.H., Dalley J.W., Glennon J.C., Robbins T.W. 5-HT2A and 5-HT2C receptor antagonists have opposing effects on a measure of impulsivity: interactions with global 5-HT depletion. Psychopharmacology 2004, 176:376-385.
111. Woolley M.L., Pemberton D.J., Bate S., Corti C., Jones D.N. The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity. Psychopharmacology 2008, 196:431-440.
112. 3H]LY341495 binding to group II metabotropic glutamate receptors in rat brain. J. Pharmacol. Exp. Ther. 2001, 298:453-460.
113. Wu J., Rowan M.J., Anwyl R. An NMDAR-independent LTP mediated by group II metabotropic glutamate receptors and p42/44 MAP kinase in the dentate gyrus in vitro. Neuropharmacology 2004, 46:311-317.
114. Yokoi M., Kobayashi K., Manabe T., Takahashi T., Sakaguchi I., Katsuura G., Shigemoto R., Ohishi H., Nomura S., Nakamura K., Nakao K., Katsuki M., Nakanishi S. Impairment of hippocampal mossy fiber LTD in mice lacking mGluR2. Science 1996, 273:645-647.
115. Zhai Y., George C.A., Zhai J., Nisenbaum E.S., Johnson M.P., Nisenbaum L.K. Group II metabotropic glutamate receptor modulation of DOI-induced c-fos mRNA and excitatory responses in the cerebral cortex. Neuropsychopharmacology 2003, 28:45-52.